Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis

Benzinga Newsdesk www.benzinga.com Positive 95.5%

Neg 0% Neu 0% Pos 95.5%

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET
Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%

Comments

No comments yet. Be the first!